Sarkozy et al. [17] demonstrated that nmGZL are heterogeneous with characteristic mutations in apoptotic pathway genes that cluster into two subsets: a first subset with mutations of TP53, BIRC6, genes related to germinal center-derived DLBCL (KMT2D, CREBBP, BCL2), and BCL2 or BCL6 translocations, indicating a close relationship to DLBCL of germinal center type; and a second subset with mutations of SOCS1 or STAT6, usually mutually exclusive with the first subset. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.